Key regions: Germany, United States, India, Japan, United Kingdom
The Anti-Rheumatic Drugs market in Mauritius has been steadily growing over the past few years.
Customer preferences: Patients in Mauritius suffering from rheumatoid arthritis are increasingly seeking out Anti-Rheumatic Drugs as a means of managing their conditions. This has led to a rise in demand for these drugs, as patients become more aware of their benefits and seek out treatment options that can help them manage their symptoms.
Trends in the market: One trend that has been observed in the Anti-Rheumatic Drugs market in Mauritius is the growing popularity of biologic drugs. These drugs are designed to target specific components of the immune system, and are often more effective than traditional disease-modifying anti-rheumatic drugs (DMARDs). As a result, many patients are opting for these drugs as a means of managing their symptoms.Another trend that has been observed is the growing prevalence of rheumatoid arthritis in Mauritius. This has led to an increase in demand for Anti-Rheumatic Drugs, as more and more patients seek out treatment options for their condition.
Local special circumstances: One of the key challenges facing the Anti-Rheumatic Drugs market in Mauritius is the high cost of these drugs. Many patients cannot afford to pay for the drugs out of pocket, and rely on government subsidies or insurance coverage to access treatment. As a result, there is a need for more affordable treatment options that can be made available to patients.
Underlying macroeconomic factors: The growth of the Anti-Rheumatic Drugs market in Mauritius is being driven by a number of underlying macroeconomic factors. These include the country's growing population, rising healthcare expenditure, and increasing prevalence of rheumatoid arthritis. Additionally, the government's efforts to improve access to healthcare services and increase funding for medical research are also contributing to the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
